ArticleImmunity, inflammation and disease2021
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
Article in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.Journal of virology · 2025Article
- Neopterin production in relation to COVID-19 in the Haut-Ogooué Province, Gabon.BMC infectious diseases · 2024Article
- Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.Signal transduction and targeted therapy · 2024Article
- Time to SARS-CoV-2 clearance in African, Caucasian, and Asian ethnic groups.Influenza and other respiratory viruses · 2024Article
- Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.The Libyan journal of medicine · 2023Article
- Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.Pathogens (Basel, Switzerland) · 2023Review
- Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.Vaccines · 2023Article
- The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency.African journal of laboratory medicine · 2023Review
- Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic.Scientific reports · 2022Article
- Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic.Journal of Zhejiang University. Science. B · 2022Article
- Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection.The Pediatric infectious disease journal · 2022Review
- Covid-19: Early Cases and Disease Spread.Annals of global health · 2022Review
- SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.Nature communications · 2021Article
- Demographic and Clinical Characteristics Associated With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon.JAMA network open · 2021Article
- SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.Microorganisms · 2021Article
- Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study.Microorganisms · 2021Review
- An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.International immunopharmacology · 2021Review
- Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic.Journal of clinical microbiology · 2021Article
- Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.Immunity, inflammation and disease · 2021Article
- The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue.Frontiers in tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic.
aimWe aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2.
methodWe have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay.
resultsSera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies.
conclusionAlthough the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.